Skip to main content

and
  1. Article

    Open Access

    Evaluating atezolizumab in patients with urinary tract squamous cell carcinoma (AURORA): study protocol for a single arm, open-label, multicentre, phase II clinical trial

    Bladder and urinary tract cancers account for approximately 21,000 new diagnoses and 5,000 deaths annually in the UK. Approximately 90% are transitional cell carcinomas where advanced disease is treated with p...

    Simon Crabb, Robin Wickens, Sarah Jane-Bibby, Denise Dunkley, Megan Lawrence in BMC Cancer (2023)

  2. Article

    Open Access

    The implementation and utility of patient screening logs in a multicentre randomised controlled oncology trial

    The utility of patient screening logs and their impact on improving trial recruitment rates are unclear. We conducted a retrospective exploratory analysis of screening data collected within a multicentre rando...

    Rebecca Lewis, Rachel Todd, Michelle Newton, Robert J. Jones, Caroline Wilson in Trials (2020)

  3. Article

    Open Access

    ATLANTIS: a randomised multi-arm phase II biomarker-directed umbrella screening trial of maintenance targeted therapy after chemotherapy in patients with advanced or metastatic urothelial cancer

    Metastatic urothelial cancer (UC) is the eighth most common cause of cancer death in the UK. Standard first-line treatment, for most patients, is cytotoxic chemotherapy. Although UC is initially sensitive to c...

    Ben Fulton, Robert Jones, Thomas Powles, Simon Crabb, James Paul, Alison Birtle in Trials (2020)

  4. Article

    Open Access

    Abiraterone acetate plus prednisone for the Management of Metastatic Castration-Resistant Prostate Cancer (mCRPC) without prior use of chemotherapy: report from a large, international, real-world retrospective cohort study

    With the recent introduction of novel treatment options, real-world data from patients with metastatic castration-resistant prostate cancer (mCRPC) are required to better understand the impact on routine clini...

    Martin Boegemann, Sara Khaksar, Guillaume Bera, Alison Birtle in BMC Cancer (2019)

  5. Article

    Open Access

    Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework

    Research has shown that recruitment to trials is a process that stretches from identifying potentially eligible patients, through eligibility assessment, to obtaining informed consent. The length and complexit...

    Caroline Wilson, Leila Rooshenas, Sangeetha Paramasivan, Daisy Elliott in Trials (2018)

  6. Article

    Open Access

    The Patient Deficit Model Overturned: a qualitative study of patients' perceptions of invitation to participate in a randomized controlled trial comparing selective bladder preservation against surgery in muscle invasive bladder cancer (SPARE, CRUK/07/011)

    Evidence suggests that poor recruitment into clinical trials rests on a patient ‘deficit’ model – an inability to comprehend trial processes. Poor communication has also been cited as a possible barrier to rec...

    Clare Moynihan, Rebecca Lewis, Emma Hall, Emma Jones, Alison Birtle in Trials (2012)

  7. Article

    Open Access

    Key issues in recruitment to randomised controlled trials with very different interventions: a qualitative investigation of recruitment to the SPARE trial (CRUK/07/011)

    Recruitment to randomised controlled trials (RCTs) with very different treatment arms is often difficult. The ProtecT (Prostate testing for cancer and Treatment) study successfully used qualitative research me...

    Sangeetha Paramasivan, Robert Huddart, Emma Hall, Rebecca Lewis, Alison Birtle in Trials (2011)